Gaurav Jain
Nephrology · Birmingham, ALNPI 1750584843
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 62.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $15,003 and has fallen 92.5% since, to $1,119 in 2025.
Across 40 payments — averaging $469.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$12K
- Fresenius USA Marketing, Inc.$2K
- Outset Medical Inc$2K
- Amgen$2K
- Nxstage Medical, Inc.$238
- Vantive US Healthcare LLC$166
- plus $556 from 6 others
What the payments were for
- Consulting fees$11,18360%
- Speaking & faculty fees$2,45013%
- Travel & lodging$2,99916%
- Food & beverage$2,16111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $11,750 |
| Fresenius USA Marketing, Inc. | 10 | $2,370 |
| Outset Medical Inc | 1 | $2,000 |
| Amgen | 6 | $1,713 |
| Nxstage Medical, Inc. | 2 | $238 |
| Vantive US Healthcare LLC | 2 | $166 |
| Baxter Healthcare | 3 | $140 |
| Boehringer Ingelheim | 1 | $125 |
| AstraZeneca | 1 | $100 |
| GSK | 5 | $88 |
| Xeris Pharmaceuticals, Inc. | 1 | $88 |
| Vifor Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavneos$1,559
- NXSTAGE SYSTEM ONE$148
- LIBERTY SELECT CYCLER$148
- Renal - Acute$102
How this compares
$18,793 in reported general payments places this provider in the 85th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 20 | $17,415 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $17,222 |
| AuryxiaFerric Citrate | 11 | $13,692 |
| KerendiaFinerenone | 12 | $12,897 |
| Sevelamer Carbonate | 39 | $5,256 |
| Clonidine | 15 | $2,713 |
| Calcium Acetate | 34 | $2,457 |
| Potassium Chloride | 52 | $1,454 |
| Gentamicin Sulfate | 37 | $1,276 |
| Hydralazine Hcl | 66 | $1,159 |
| Tamsulosin Hcl | 52 | $988 |
| Potassium Citrate ErPotassium Citrate | 13 | $984 |
| Losartan Potassium | 98 | $960 |
| Carvedilol | 72 | $896 |
| Lisinopril | 98 | $789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $125 | $17,41520 claims |
| AstraZenecaLokelma | $100 | $17,22220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 nephrology providers in Alabama.
Other nephrology in Birmingham
- Dana RizkBirmingham$196K
- Eric WallaceBirmingham$172K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
- Ashita TolwaniBirmingham$56K
- Song Ching OngBirmingham$36K
- Orlando GutierrezBirmingham$26K
- Ammar AlmehmiBirmingham$26K
- Jared CookBirmingham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.